Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tesaro
Fierce Pharma
GSK's Tesaro, AnaptysBio lock horns over Jemperli agreement
Some four years into Jemperli’s commercial run, a rift has emerged between GSK unit Tesaro and the cancer drug's original developer, AnaptysBio.
Fraiser Kansteiner
Nov 21, 2025 9:46am
Xencor sells ex-lead drug to Tesaro founder in backloaded deal
Nov 22, 2021 8:45am
AbbVie, Roche top data transparency list in new Yale report
Jul 21, 2021 10:15am
GSK posts middling data from PD-1 Tesaro buyout drug
Apr 24, 2020 8:35am
GlaxoSmithKline talks up new R&D focus, keeps mum on M&A
Feb 6, 2020 7:34am
JPM Tuesday: Pfizer's pipeline, 2020's bolt-on deals
Jan 15, 2020 7:50am
